Rett syndrome

Unravel Biosciences licenses Wyss Institute platform technology from Harvard and Tufts University to decode, model, and treat complex diseases

Retrieved on: 
Tuesday, September 27, 2022

Boston, MA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Today, Unravel Biosciences and the Wyss Institute for Biologically Inspired Engineering at Harvard University announced that Unravel has licensed a drug discovery platform technology from Harvard and Tufts University.

Key Points: 
  • Boston, MA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Today, Unravel Biosciences and the Wyss Institute for Biologically Inspired Engineering at Harvard University announced that Unravel has licensed a drug discovery platform technology from Harvard and Tufts University.
  • The company will use the technology, invented at the Wyss Institute, to decode and model complex diseases to accelerate the development of new and more effective therapies.
  • In contrast, we start with an individual patient and ask, What is different about this patient thats causing this disease?
  • Components of the CogniXense platform are being further developed at the Wyss Institute, and are being used in its Biostasis and CircaVent projects.

Duncan NRI at Texas Children's Hospital Accelerates Neurological Research and Therapies with Historic $10M Gift from The Blue Bird Circle

Retrieved on: 
Friday, September 23, 2022

HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.

Key Points: 
  • HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.
  • This historic donation is being made to commemorate the Blue Bird Circle's upcoming centennial anniversary and brings the organization's gifts to Texas Children's to over $25 million which will help advance life-changing neurological research at the Duncan NRI.
  • At Texas Children's Hospital Blue Bird Clinic, Blue Bird volunteers log more than 5,000 hours a year in administrative assistance the equivalent of three full-time employees.
  • The volunteers' time, effort, and donations help support The Blue Bird Circle Clinic for Pediatric Neurology at Texas Children's Hospital.

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, September 1, 2022

Acadia is advancing breakthroughs in neuroscience to elevate life.

Key Points: 
  • Acadia is advancing breakthroughs in neuroscience to elevate life.
  • For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most.
  • We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinsons disease psychosis.
  • Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome and neuropsychiatric symptoms in central nervous system disorders.

Vyant Bio to Deliver a Live Presentation at the Skyline Signature Series™ on Thursday, September 8, 2022

Retrieved on: 
Thursday, September 1, 2022

CHERRY HILL, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will be presenting at the Skyline Signature Series™ on Thursday, September 8, 2022.

Key Points: 
  • The Skyline Signature Series provides public companies with a convenient and effective forum to communicate their story to a diverse audience of financial professionals through live virtual presentations.
  • Skyline Corporate Communications Group, LLC will be compensated by Vyant Bio for providing investor relations services relating to the Companys securities.
  • Skyline delivers strategic assistance for companies in the financial markets and investment community by effectively communicating their corporate message and competitive advantages.
  • For more information, please visit or follow Vyant Bio at:

Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Wednesday, August 31, 2022

The presentation slides will also be available in the Investors section of the Vyant Bio website.

Key Points: 
  • The presentation slides will also be available in the Investors section of the Vyant Bio website.
  • If you are an institutional investor and would like to listen to the Company's presentation, please click on the link: https://hcwevents.com/annualconference/ to register for the conference.
  • Vyant Bio will also be available for outside 1:1 meetings in New York City during and after the H.C. Wainwright Global Investment Conference.
  • Vyant Bio, Inc. (Vyant Bio or the Company) (Nasdaq: VYNT) is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics.

Proactive news headlines including Auxico, Twitter, Montero Mining, Harbor Custom Development, Todos Medical, Sidus Space

Retrieved on: 
Tuesday, August 23, 2022

With six offices on three continents, Proactive works with innovative growth companies quoted on the worlds major stock exchanges, helping executives to engage intelligently with investors.

Key Points: 
  • With six offices on three continents, Proactive works with innovative growth companies quoted on the worlds major stock exchanges, helping executives to engage intelligently with investors.
  • In 2020, Proactive featured in 809 million search results, our content was viewed over 165 million times and our readers spent over 10 million hours on our websites.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected].

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease

Retrieved on: 
Tuesday, August 23, 2022

NEW YORK, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, today reported a relevant new peer-reviewed publication in the journal Science Translational Medicine, titled "Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer's disease."1

Key Points: 
  • "1
    One of the featured observations was an increase in SIGMAR1 expression in the early stages of AD.
  • Combinatorial therapy has been suggested as a treatment strategy; however, the existence of drug-drug interaction is a concern.
  • Hence, there is a need to develop drug molecules that can target multiple pathways to halt disease progression and improve memory function.
  • Anavex Life Sciences' precision medicine platform includes small molecule drug lead candidate ANAVEX2-73 for the treatment of Alzheimer's disease, Parkinson's disease, and Rett syndrome and ANAVEX3-71 for schizophrenia, frontotemporal dementia, and Alzheimer's disease.

Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights

Retrieved on: 
Monday, August 22, 2022

CHERRY HILL, N.J., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning to elucidate disease pathophysiology and identify and validate drug targets for rare CNS genetic disorders. Today, Vyant Bio filed its Form 10-Q for the Second Quarter 2022 with the Securities and Exchange Commission (“SEC”) and will discuss its Second Quarter 2022 highlights and business updates this afternoon in a conference call and webcast scheduled for 4:30 pm ET.

Key Points: 
  • Today, Vyant Bio filed its Form 10-Q for the Second Quarter 2022 with the Securities and Exchange Commission (SEC) and will discuss its Second Quarter 2022 highlights and business updates this afternoon in a conference call and webcast scheduled for 4:30 pm ET.
  • The Companys loss from continuing operations aggregated $4.3 million in the second quarter of 2022, compared with $4.0 million in the second quarter of 2021.
  • Net loss from discontinuing operations was $1.5 million for the second quarter of 2022, compared with $232 thousand for the second quarter of 2021.
  • Vyant Bios management will host a conference call on Monday, August 22, 2022 at 4:30 pm ET to discuss the second quarter and first half 2022 results and provide strategic business updates, as well as answer questions.

Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022

Retrieved on: 
Friday, August 19, 2022

The conference call and webcast details are also included inside the Investors section of the Vyant Bio corporate website at www.vyantbio.com .

Key Points: 
  • The conference call and webcast details are also included inside the Investors section of the Vyant Bio corporate website at www.vyantbio.com .
  • Vyant Bio, Inc. (Vyant Bio or the Company) (Nasdaq: VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics.
  • Vyant Bio has built a platform of therapeutics seeking to treat neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett Syndrome (Rett), CDKL5 Deficiency Disorders (CDD), and Parkinsons Disease.
  • For more information, please visit or follow Vyant Bio at:

Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast

Retrieved on: 
Monday, August 15, 2022

CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (Vyant Bio or Company) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Key Points: 
  • CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (Vyant Bio or Company) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.
  • Today, Vyant Bio announced that it is postponing its investor conference call for the second quarter and first half of 2022, originally scheduled for Monday, August 15, 2022 at 4:30 pm ET.
  • Vyant Bio, Inc. (Vyant Bio or the Company) (Nasdaq: VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics.
  • For more information, please visit or follow Vyant Bio at: